by Dr. Alyssa Master | Aug 24, 2020
The surge of cellular T cell-based immunotherapies has prompted more and more researchers to take an interest in these specialized immune cells. Whether you are brand new to the cell therapy field or an experienced immunologist, learning to work with a new cell type...
![Top 10 Cell Therapy Conferences for 2020 [UPDATED]](https://nucleusbiologics.com/wp-content/uploads/2020/07/newbannerconferencesimage-1.png)
by Dr. Alyssa Master | Jul 8, 2020
While COVID-19 may have prevented many planned cell therapy conferences from meeting in-person, a great many have become virtual, and some are still planning to go on in-person. Here are 10 conferences we want to attend this year, from July to November. Don’t miss...
![Kymriah vs. Yescarta [UPDATED]](https://nucleusbiologics.com/wp-content/uploads/2019/05/kymriah-vs-yescarta-feat.jpg)
by Dr. Alyssa Master | Aug 20, 2019
Kymriah® and Yescarta® are currently the only two FDA-approved CAR-T cell therapy products available on the market in the United States. Do you have trouble distinguishing between them? We created a simple chart to showcase some of the similarities and differences...
by Ashley Fallon | Jul 10, 2019
The cell therapy field has experienced rapid growth over the last few years! As our knowledge increases, so do the number of cell and gene therapy conferences. There are so many to choose from in North America, but we can’t ignore the rest of the world! Check...
by Dr. Alyssa Master | Feb 9, 2019
Companies with breakthrough CAR T products need to focus not just on the science but also on how to successfully bring their therapies to market. Because cell and gene therapies are unlike conventional treatments, everything from sales & marketing to manufacturing...
by Dr. Alyssa Master | Jan 30, 2019
Do you need a scientific crash course in CAR T cell therapy? The Nucleus Team has curated three great scientific reviews written by leaders in the field of CAR T cells so you can stay up-to-date on mechanisms of action, first and second generation CARs, and challenges...
